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Gastroretentive microparticles for drug delivery applications  
Abstract 
Many strategies have been proposed to explore the possibility of exploiting 
gastroretention for drug delivery. Such systems would be useful for local delivery, for 
drugs that are poorly soluble at higher pH or primarily absorbed from the proximal 
small intestine. Generally, the requirements of such strategies are that the vehicle 
maintains controlled drug release and exhibits prolonged residence time in the 
stomach. Despite widespread reporting of technologies, many have an inherent 
drawback of variability in transit times. Microparticulate systems, capable of 
distributing widely through the GI tract, can potentially minimize this variation.  While 
being retained in the stomach, the drug content is released slowly at a desired rate, 
resulting in reduced fluctuations in drug levels. This review summarises the 
promising role of microencapsulation in this field, exploring both floating and 
mucoadhesive microparticles and their application in treatment of H. pylori, 
highlighting the clinical potential of eradication of this widespread infection.  
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1. Introduction 
The oral delivery route is the most common of all drug administration routes and 
accounts for about half of all drug administration. This is partly due to the fact that 
the gastrointestinal tract offers a wide range of flexibility in dosage form design than 
other routes. Also, it is a convenient route of administration for easy access to the 
systemic circulation.  However, drug absorption via this route can be unsatisfactory 
and variable even following promising in vitro release profiles (Davis, 2005, Streubel 
et al., 2006). This makes it difficult to predict the in vivo performance of a drug 
delivery system (DDS), even though the in vitro data are reproducible. There are 
several physiological factors that could work against achieving successful delivery of 
drugs via the oral route and such factors include unpredictable gastric emptying 
times, shorter gastrointestinal transit time of the dosage form, partial drug release 
from the dosage form and the absorption site of the particular drug. 
The average residence time of formulations in the stomach depends on the type of 
dosage form.  Tablets, pellets, capsules and solutions have an average residence 
time of 2.7 ± 1.5  hours, 1.2 ± 1.3 hours, 0.8 ± 1.2 hours and 0.3 ± 0.07 hours 
respectively in the fed state (Chawla et al., 2003). The effective duration of release 
from non-retentive controlled release delivery systems such as oral matrix or osmotic 
systems cannot not extend beyond normal gastrointestinal (GI) transit time, and so is 
unpredictable and limited to around 12 hours maximum. 
2. Gastroretentive systems  
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Gastroretentive dosage forms (GRDFs) are designed to be retained in the stomach 
for an extended duration in order to improve the  residence time of dosage forms in 
the stomach, thereby leading to enhanced bioavailability of the drug. 
Not all drugs, however, are good candidates for gastroretention, but those that are 
and have been formulated in a range of gastroretentive systems include:  
 drugs that act locally in the stomach, e.g. misoprostol (Oth et al., 1992), 
antacids (Fabregas et al., 1994) and antibiotics (Yang et al., 1999, Whitehead 
et al., 2000)  
 drugs that are absorbed primarily in the stomach, e.g. metronidazole (Adebisi 
and Conway, 2010) 
 drugs that are poorly soluble at alkaline pH, e.g. diazepam (Sheth and 
Tossounian, 1984) and verapamil hydrochloride (Streubel et al., 2002); 
thereby preventing solubility from being the rate–limiting step to the 
absorption of the drug by restricting the drug to the stomach 
 drugs that have a narrow absorption window in the stomach or in the upper 
small intestine, e.g. levodopa (Erni and Held, 1987), para-amino benzoic 
acids (Ichikawa et al., 1991a, Ichikawa et al., 1991b)  and furosemide (Menon 
et al., 1994) 
 drugs that are absorbed rapidly from the GI tract, e.g. amoxicillin  
 drugs that degrade or are unstable in the colonic / intestinal environment, e.g. 
captopril (Matharu and Sanghavi, 1992, Nur and Zhang, 2000) and 
metronidazole  (Nayak et al., 2010). 
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2.1. Requirements for gastroretentive devices 
In order for a drug dosage form to achieve gastroretention, it must satisfy certain 
conditions. One major requirement is that the dosage form must be strong enough to 
withstand the peristaltic waves of the stomach, the contractions and forces within the 
stomach. Another important requirement is that it must be easily removed from the 
stomach, once the drug content is released from the delivery device (Anilkumar, 
2008). 
2.2. Physiology of the stomach 
The stomach is the organ involved in the liquefaction of food and it also releases the 
churned food in a controlled manner into the intestines. It is divided into two major 
parts based on their functions. The fundus and the body of the stomach produce 
contractions in the muscle walls and cause compaction of the stomach contents, 
while the antrum causes peristaltic phase movement leading to the comminution of 
the food into small particles of about 2 mm. For the stomach contents to be able to 
pass through the pyloric valve into the small intestine, the particle size should be 
within the range of 1 to 2 mm (Deshpande et al., 1996). 
In the fasted state, the stomach has a residual volume of 25-50 ml (Waugh et al., 
2001) with a small amount of fluid and a pH ranging from 1 to 3 (Bowman et al., 
1968). The GI tract is in a state of continuous motility. The motility is in two modes –
the inter-digestive motility pattern (also called the migrating motor complex) and 
digestive motility pattern.   
The inter-digestive motility pattern presides in the fasted state, with the main function 
being the clearing of the stomach of the residual contents of the upper GI tract. 
6 
 
Under fasted conditions, the inter-digestive myoelectric motor complex (IMMC)  is a  
2-hour cycle of peristaltic activity that regulates motility patterns (Washington et al., 
2001). It is organised in cycles of activity and quiescence (Deshpande et al., 1996). 
Each of the cycles lasts for a period of 90 to 120 minutes consisting of four phases 
and the duration of the phases depends on the concentration of the hormone, 
motilin. The ingestion of food interferes with the inter-digestive motility cycle and the 
digestive cycle takes over. The digestive cycle is induced 5-10 minutes after the 
ingestion of food and remains active for as long as there is food in the stomach. 
Therefore, the larger the meal, the longer the period of fed activity, with usual times 
being 2-6 hours and more usually 3-4 hours with contractions similar to Phase II of 
IMMC (Pawar et al., 2011). 
For a formulation to be gastroretentive, it must be able to resist the pressures and 
forces of the IMMC, especially the strong intense contractions of phase III, 
(Soppimath et al., 2001a) for a considerable period of time. The gastric residence 
time (GRT) of a particular formulation will depend on the stage of the IMMC is active 
at the time of drug administration. 
In the fed state, after the churning of food to smaller particle sizes, the residence 
time of the food, depends on what type of food is consumed. Liquids and small food 
particles will be easily transferred into the duodenum, while solids and larger food 
particles are removed much more slowly (Conway, 2005). 
2.3. Factors affecting gastric residence time 
 There are several factors affecting the GRT of dosage forms (Gruber et al., 
1987) and they include: 2.3.1. Fed or fasted conditions – GRT is longer in the 
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fed state than in the fasted state. In the fasted state, the gastric residence of 
dosage forms is usually not longer than an hour and it is common for dosage 
forms to move rapidly through the small intestine, for not more than 3 hours 
(Khandai et al., 2010, Naisbett and John, 1995).  This phenomenon is due to 
the fact that the IMMC moves the undigested food material from the stomach 
and if the time of drug administration occurs around the time of IMMC, the 
formulation will be expelled out of the stomach, leading to a short gastric 
residence. In the fed state however, the IMMC (related to fasted state) is 
delayed, thereby increasing the gastric residence time. Lin et al. observed that 
stomach emptying of 1.6 mm diameter spheres were affected by a 300 g 
steak meal (Lin et al., 1992). The presence of food caused a delay in the 
housekeeper wave. Most of the drug particles were uniformly distributed 
among the food particles in the stomach, thereby delaying the stomach 
emptying process. Also, when 3-5 mm diameter tablets were taken with a 
meal, the emptying process was delayed in humans (Khosla et al., 1989). In 
addition, a high fat meal may delay gastric emptying from 3 to 5 hours (Gad, 
2008)2.3.2. Density of formulation - The density of a dosage form has an 
impact on its ability to stay in the stomach for a prolonged period of time 
(Figure 1). A high density formulation e.g. coated pellets, which have a density 
greater than that of gastric contents (1.004 g/cm3), will sink to the lower part of 
the antrum. This type of coating is achieved by the use of heavy inert 
materials such as barium sulphate, zinc oxide, and titanium dioxide (Patel, 
2007). In addition, a low density formulation, with a density less than the 
density of the gastric contents, is expected to remain buoyant in the gastric 
fluid (Singh and Kim, 2000). For example, the hypotensive action of diltiazem 
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was heightened when administered to humans in a floating controlled release 
tablet compared to an equivalent non-floating tablet  (Gu et al., 1992). For 
particulate systems, it has been reported that particles of different densities 
ranging from 0.5 to 2.9 g/cm3, emptied from the stomach of fasted dogs in a 
similar manner (Gruber et al., 1987). The results by Gruber and co-workers 
are similar to those observed in fasted humans as there was no difference 
observed between the rate of gastric emptying of floating (density=0.96 g/cm3) 
and non-floating (1.96 g/cm3) single unit dosage forms (Davis et al., 1986). 
Inconsistencies and variability in results are likely to be a consequence of fed 
versus fasted conditions in the stomach, thereby reducing the impact of 
density on gastroretention. 
 
 2.3.3 Size of formulation - If the size of a dosage form is larger than the 
diameter of the pylorus, the dosage form will be retained in the stomach, even 
during the housekeeper wave. Therefore, such a dosage form will be initially 
of a smaller size to facilitate swallowing, then it increases in size when it gets 
to the stomach (Streubel et al., 2006). The size of the dosage form required, 
may be greater  than 5 cm in length and a diameter greater than 3 cm 
(Klausner et al., 2003a). A diameter of more than 7.5 mm is also stated to 
favour gastroretention more than dosage forms with diameter, greater than 
9.9 mm (Timmermans and Moes, 1994). 
 2.3.4 Shape of formulation -The shape of the dosage form has an effect on its 
gastroretentive ability. Ring-shaped and tetrahedral devices have been shown 
to demonstrate a longer GRT , in comparison with dosage forms of other 
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shapes (Garg and Sharma, 2003). In addition, ring-shaped GRDFs with a 
flexural modulus of 22.5 kilo pounds per square inch and tetrahedral GRDFs 
(modulus of 48 kilo pounds per square inch) were reported to exhibit 90-100% 
retention at 24 hours, compared to dosage forms with shapes defined as 
continuous stick, planar disc, planar multi-lobe and string (Pawar et al., 2011). 
 2.3.5. Single or multiple unit formulation - When compared to single unit 
formulations, multiple unit formulations show more predictable and more 
reliable gastric emptying. Single unit formulations exhibit the “all or nothing 
concept ’’ and failure of the unit, while in the case of multiple unit systems, the 
particles are distributed freely throughout the GI system and their distribution 
or movement is less affected by the transit time than with single unit dosage 
form (Bechgaard and Ladefoged, 1978, Whitehead et al., 1998). Also, as the 
drug release kinetics of multiple unit systems are more predictable, there is a 
reduced likelihood of localised mucosal damage or dose dumping (Rouge et 
al., 1997), and they allow the co-administration of units with different release 
profiles or those containing substances that are incompatible (Ishak et al., 
2007). 
 2.3.6. Nature of meal and food intake - Factors such as the nature of food, 
frequency of feeding and caloric content have important effects on gastro- 
retention of dosage forms. Fatty acid salts and indigestible polymers such as 
cellulose, poly-dextrose and reffinose tend to extend GRT. . The gastric 
retention of water was reported to follow an expediential pattern with a half life 
(t1/2) of 10 minutes (Hunt, 1968). An increase in the volume of water increases 
the gastric emptying; however, gastric emptying of a liquid meal can be 
10 
 
affected by the chemical and osmotic properties of the meal.  Foods high in 
proteins and fats can increase GRT by 4-10 hours. The gastric retention of 
dosage forms is improved by the presence of food in the stomach; this 
increased residence of drug in the stomach therefore, helps in improving the 
bioavailability of the drug. Enteric-coated or enteric matrix tablets may be 
retained longer, if administered with heavy meals or breakfast (Gad, 2008). 
 2.3.7. Gender - Females have been found to show a comparatively lower 
mean ambulatory GRT, than their male counterparts.  The gastric emptying 
time of the Heidelberg capsule is slower in women than in men (Mojaverian et 
al., 1988). Also, the mean GRT in females (4.6 ±1.2h) is higher than in males 
(3.4 ± 0.6h) of the same age and race. 
 2.3.8. Posture - It has been reported that posture does not have a significant 
effect on GRT (Mojaverian et al., 1988); however, another study showed that 
for both floating and non-floating systems, the GRTs of the dosage forms vary 
based on the subject’s posture (Van Gansbeke et al., 1991). Floating systems 
taken by subjects in an upright position were found to float for a longer period 
of time, thereby extending gastroretention. However, non-floating systems 
settled to the bottom of the stomach and were easily evacuated by peristaltic 
contractions. In a supine position however, the reverse occurred as the 
floating units were more easily emptied from the stomach, than the non-
floating units (Timmermans and Moes, 1994). 
 2.3.9. Concomitant drug administration- Examples of drugs that have an effect 
on GI transit times include anti-cholinergic drugs such as atropine, opiates, 
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e.g. codeine and pro-kinetic drugs, e.g. metoclopramide. All these prolong 
GRT, while drugs like octreotide and erythromycin enhance gastric emptying.  
 2.3.10. Biological factors- disease states such as  Crohn’s disease have been 
associated with delayed gastric emptying (Grill et al., 1985, Annese et al., 
1995). Diabetes has also been linked to delayed gastric emptying with this 
delay occurring in 30-50% of patients with long standing diabetes mellitus 
(Horowitz et al., 1996). Duodenal ulcers lead to an increase in gastric 
emptying, while gastric ulceration reduces antral motility causing a normal 
emptying of liquids but resulted in delayed emptying of solids (Miller et al., 
1980). 
 2.3.11. Age – The effect of age on the gastric residence of the Heidelberg 
capsule was assessed in 12 healthy elderly males over 65 years. It was 
observed that the mean GRT after a 500-kcal breakfast. was significantly 
longer, compared to that observed in young male volunteers (Mojaverian et 
al., 1988).                                                   
3. Gastroretentive dosage forms  
Various approaches have been developed to achieve gastroretention. Passage 
delaying agents such as triethanolamine myristate (Gröning and Heun, 1984),  have 
been used to have an influence on gastric transit of DDS  based on the fact that the 
lipid vehicles tend to reduce the motility of the stomach. However, this deliberate 
slowing down of gastric motility may have an effect on the emptying of the entire 
contents of the stomach.   
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DDS  have been developed to achieve gastroretention and they include bioadhesive 
systems (Ponchel and Irache, 1998); swelling and expanding systems (Urguhart and 
Theeuwes, 1994); high density systems (Rednick and Tucker, 1970); floating 
systems (Deshpande et al., 1996), and modified shape systems (Fix et al., 1993).  
3.1. Swelling and Expandable Systems  
Swelling systems exploit the restrictions on the removal of large particles from the 
stomach, if they are larger than the pyloric sphincter opening (Nayak et al., 2010).  . 
Important features of these formulations are that the dosage form must be small 
enough for it to be easily swallowed; the onset of swelling must be fast, so as to 
prevent its evacuation from the stomach, before getting a chance to swell (Conway, 
2005); it must not cause any form of gastric obstruction, either singly or by 
accumulation (Nayak et al., 2010) and must regain a small size to be evacuated after 
complete drug release (Groning et al., 2007). 
The increase in size of the formulation is normally achieved by swelling (through the 
process of osmosis) or by unfolding on contact with the contents of the stomach 
(Klausner et al., 2002). There are several drawbacks to the use of this kind of 
system, as large single unit dosage forms may cause obstruction, intestinal 
adhesion, and gastropathy (Klausner et al., 2003b). Such dosage forms should not 
possess sharp edges or cause local damage to the stomach on extension and the 
system must be made from biodegradable polymers.   
 
3.2. High density systems  
High density systems are dosage forms that have a density greater than the density 
of normal stomach contents which is 1.004 g/cm3 (Figure 1). The density of the 
13 
 
formulation should be close to 2.5 g/cm3, for it to be retained in the stomach for any 
considerable length of time (Clarke et al., 1993). Rouge et al., also reported that 
above densities of 2.4 - 2.8 g/cm3, formulations can be retained in the lower part of 
the stomach (Rouge et al., 1998). Inert materials used to increase the density of 
formulations are used either by coating the drug with it  or by mixing the material with 
the drug (Vyas and Khar, 2006). On addition of such inert materials, the formulation 
density can increase by up to 1.5--2.4 g/cm3 (Clarke et al., 1993). One major 
drawback, however is that they are difficult to manufacture, requiring relatively large 
quantities of active drug as the dry material constituent of the formulation reacts with 
the gastric fluid to release its contents. There is no formulation utilising this strategy 
currently on the market (Nayak et al., 2010, Garg and Sharma, 2003) and in vivo 
data in animal ) or clinical studies  are also rather scarce. 
 
3.3. Bioadhesive systems/ Mucoadhesive systems   
 Bioadhesive DDS , as introduced in the 1980s,  adhere to epithelial surfaces, thus  
maintaining  a more intimate contact with the mucosal barrier (Park and Robinson, 
1984) and thereby prolonging GRT due to this feature. A subset of bioadhesive 
systems is mucoadhesive systems, which adhere to the thick mucus gel layer that 
covers the mucosal surfaces in the stomach (Conway, 2005). Chitosan for example, 
has been used to achieve mucoadhesion (Lehr et al., 1992) and adhesion to porcine 
stomach (Gåserød et al., 1998) in some formulations. The concept of mucoadhesive 
systems is based on the self protecting mechanism of the GI tract. Mucus plays a 
cytoprotective role by protecting the surface mucosal cells from acid and peptidases. 
It  is a viscoelastic, gel-like, stringy slime consisting mainly of glycoproteins and 
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serves as a lubricant for the passage of solids and as a barrier to antigens, bacteria 
and viruses (Chawla et al., 2003). The process of mucoadhesion is complex and its 
mechanism, has been explained through various theories such as electrical,, 
adsorption, wetting and diffusion theories (Peppas and Buri, 1985, Park and 
Robinson, 1987, Rillosi and Buckton, 1995). Mucoadhesion has been said to occur 
in two stages ; the contact (wetting) stage and then the consolidation stage, which is 
the stage where adhesive interactions are established (Smart, 2005). The mucosal 
surface is negatively charged; therefore a polymer that has a positive charge might 
assist the mucoadhesion process. An initial step of mucoadhesion could be 
electrostatic attraction, followed by mechanical interlocking of the polymer chains, 
van der Waals force, hydrogen bonding and other forces (Lehr et al., 1993). The 
different mechanisms of bioadhesion are summarized in Table 1. 
 
One drawback associated with such systems is that the mucus on the stomach walls 
is constantly being renewed, thereby making adherence of a formulation to this 
mucus unpredictable (Chun et al., 2005b). In addition, the contents of the stomach 
are highly hydrated, thereby reducing the level of adhesiveness of the polymers. 
Other factors that can affect effective in vivo mucoadhesion include the composition 
of mucus, different behaviour of mucoadhesive devices over the pH range, and 
disease conditions (Vasir et al., 2003). Also, the prospect of oesophageal binding 
might be daunting, regarding the safety aspects of such formulations (Wang et al., 
2000). The specificity of the formulation could also be a major drawback, as it is 
difficult to specifically target bioadhesive polymers to the gastric mucosa, for 
example,  Carbopol® will adhere to various surfaces (Khosla and Davis, 1987). 
15 
 
However, the advantages of such systems in the treatment of H. pylori infections 
may outweigh these concerns, because they have the potential to maintain contact 
with the mucus layer and provide controlled release of drugs e.g. antibiotics, in a 
localised environment. An additional consideration with this application is the 
avoidance of any local drug overdose, which could lead to irritation of the gastric 
mucosa (Ch'ng et al., 1985).  
 
3.4. Floating systems  
Early studies based on floating systems date as far back as 1968 (Davis, 1968). 
Floating delivery systems (Figure 1) generally have a bulk density, that is less than 
the density of the gastric contents and thus remain buoyant in the stomach, without 
affecting the gastric emptying rate for a prolonged period of time. A floating system 
could lead to high drug levels in the fundal area of the gastric mucosa and this may 
be a useful strategy for the delivery of narrow spectrum antibiotics for peptic ulcer 
disease (Umamaheswari et al., 2002) and for drugs that are primarily absorbed in 
the stomach or the upper small intestine (Sungthongjeen et al., 2006), e.g. 
metronidazole. 
The drug content should be released slowly as the dosage form remains floating on 
the gastric contents. At the end of the release period, the DDS should exit from the 
stomach. This type of DDS has been demonstrated to increase gastroretention and 
reduce fluctuations in drug plasma concentrations (Singh and Kim, 2000).  
 
3.4.1. Specific criteria for a floating DDS:-  
 It must have a structure to form a cohesive gel barrier. 
16 
 
 It must maintain a density lower than that of gastric contents (1.004-1.010 
g/cm3). 
 It should dissolve slowly enough to serve as a drug depot (Desai, 2007).   
Floating systems include designs such as hydro-dynamically balanced systems 
(HBS), gas generating systems, raft forming systems and hollow microspheres. 
These systems can be achieved by entrapping air into the formulation, e.g. hollow 
microspheres (Krogel and Bodmeier, 1999) or through the inclusion of oils 
(Sriamornsak et al., 2004) or foam powder (Streubel et al., 2002). Floating dosage 
forms include granules (Yuasa et al., 1996), powders (Dennis and Timmins, 1992), 
capsules (Franz and Oth, 1992), tablets (Sheth and Tossounian, 1979), laminated 
films (Machida et al., 1989) and hollow microspheres (Kawashima et al., 1991). 
There are several advantages attributed to the use of floating DDS including 
improvement in patient compliance; achievement of better therapeutic effect of drugs 
with a short half life; enhancement of absorption of drugs, which are soluble primarily 
in the stomach and achievement of site-specific delivery of drug to the stomach 
(Pawar et al., 2011). 
The limitations to the use of these formulations, include the requirement for the 
presence of fluids in the stomach (dosage form is administered typically with fluid of 
about 200-250 ml (Soppimath et al., 2001a)), in order to maintain buoyancy effect of 
the formulation in the stomach. Also, drugs that cause gastric mucosa irritation and 
those with  solubility and/or stability issues in gastric fluids and those that cause 
gastric mucosa irritation like biomolecules, such as proteins and peptides (which are 
liable to proteolysis in gastric fluid) are not suitable for incorporation into this type of 
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delivery system. In addition, drugs which are well absorbed along the entire GI tract 
and undergoes significant first pass metabolism are not suitable candidates, since 
the slow gastric emptying could lead to a reduction in systemic bioavailability (Pawar 
et al., 2011). 
 3.4.2. Formulations for floating systems   
 Floating systems can be divided into two categories: - gas generating systems and 
non-effervescent systems (Garg and Gupta, 2008).  
3.4.2.1. Gas generating / Effervescent systems 
 These are systems designed so that when they contact the gastric contents, gas 
bubbles are released causing the dosage form to float on gastric contents. This is 
achieved by the incorporation of vacuum, air or inert gas into a floatation chamber 
(Iannuccelli et al., 1998). The gas can be added to the formulation by the 
volatilization of an organic solvent such as ether or cyclopentane, causing inflation 
on contact with gastric fluid or through carbon dioxide produced due to the chemical 
reaction between organic acids and carbonate-bicarbonate salts (Sakr, 1999).  
These formulations make use of swellable polymers such as methylcellulose and 
hydroxylpropylmethylcellulose (HPMC); polysaccharides (e.g. chitosan) and 
effervescent materials, such as sodium bicarbonate, citric acid (Rubinstein and 
Friend, 1994), tartaric acid or floating chambers that contain liquids that turn into a 
gaseous state at body temperature (Pawar et al., 2011). The required stoichiometric 
ratio of citric acid and sodium bicarbonate for the generation of gas has been 
reported to be 0.76:1 (Garg and Sharma, 2003). 
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 In a study in 1978, Umezawa developed floating pepstatin minicapsules containing 
sodium bicarbonate, coated with an inner HPMC layer and an outer pepstatin layer. 
On contact with gastric fluid, there is a release of carbon dioxide leading a   GRT of  
about 3- 5 hours and prolonged the release of drug from the formulation (Umezawa, 
1978) . 
Other floating formulations include those using a combination of sodium alginate and 
sodium bicarbonate (Stockwell et al., 1986); floating mini-capsules consisting  a core 
of sodium bicarbonate, lactose and polyvinyl-pyrrolidone, coated with HPMC and 
systems produced using ion exchange resin technology (Garg and Gupta, 2008). 
The main drawback of these systems is that they do not float immediately after 
swallowing, as there is a lag time between swallowing and the release of gas. In 
order for the formulation to be effective, the lag time has to be minimised to avoid  
premature evacuation from the stomach (Streubel et al., 2003). However, there are 
many commercially available pharmaceutical products utilising this approach, such 
as Gaviscon® and Madopar® HBS capsule (Singh and Kim, 2000). 
3.4.2.2.  Non-effervescent Systems  
In non-effervescent systems, air entrapped in the swollen polymer confers buoyancy 
on the dosage forms. The systems absorb gastric fluid, on contact, swell and form a 
colloidal gel barrier (Sheth and Tossounian, 1979), that limits the rate of fluid 
absorption into the device and subsequently drug release (Sheth and Tossounian, 
1984). The air trapped by the swollen polymer, lowers the density and confers 
buoyancy to the dosage form. A common way of incorporating drug into this type of 
formulation is by mixing the drug with a gel (typically with a high concentration of 
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about 25-75 %w/w) that swells on contact with gastric fluid, while still maintaining its 
integrity of shape and a bulk density less than 1.004 g/cm3. Commonly used 
polymers for this type of formulation include, cellulosic hydrocolloids such as HPMC 
and matrix-forming polymers such as poly-acrylate, polycarbonate, polystyrene and 
poly-methacrylate. Other excipients include  polyvinyl acetate, Carbopol®, agar, 
sodium alginate, polyethylene oxide and polycarbonates (Garg and Gupta, 2008).  
 
Non-effervescent systems are sub-divided into hydrodynamically balanced systems, 
alginate beads, microporous compartment systems and hollow microspheres:- 
3.4.2.2.1. Hydrodynamically balanced systems (HBS) introduced in 1975 by 
Sheth and Tossounian are single unit dosage forms, containing the active ingredient 
with one or more gel forming hydrocolloids, which remain floating on stomach 
contents. These systems are suitable for drugs that have a better solubility in the 
acidic pH of the stomach and those that have a specific site of absorption in the 
upper part of the small intestine (Rocca et al., 2003).  Excipients commonly used in 
this type of formulations include HPMC, hydroxyethylcellulose (HEC), sodium 
carboxymethylcellulose (NaCMC), polycarbophil, polyacrylate, polystyrene, agar, 
carrageenans or alginic acid (Hwang et al., 1998, Reddy and Murthy, 2002, Nayak et 
al., 2010).  
 
3.4.2.2.2. Alginate beads 
 
Floating alginate dosage forms were introduced in the 1980s (Stockwell et al., 1986). 
Alginates are linear anionic block copolymer hetero-polysaccharides made up of 
monomers of (β-d-mannuronic acid) (M) and its C-5 epimer (α-1-guluronic acid) (G) 
residues, linked to one another by 1, 4-glycosidic linkages. They are extracted from 
20 
 
the cell walls of various species of brown algae (Sanford and Baird, 1983). Alginates 
from different seaweeds can have different ratios of the component monomers. The 
ratio and the distribution of the monomers in the alginate chain do have an effect on 
gel formation and strength. Hydrogel formation occurs by  ionotropic gelation on 
reaction with bivalent alkaline earth metals such as Ca2+, Sr2+ and Ba2+ or trivalent 
Fe3+ and Al3+ ions, due to an ionic interaction and intra-molecular bonding between 
the carboxylic acid groups present on the polymer backbone and the cations (Patel 
et al., 2006). The complexation of the polyguluronic sequences of alginate by Ca2+ 
results in the formation of a three-dimensional network usually described by the ‘egg 
box’ model (Grant et al., 1973), giving rise to formation of calcium alginate hydrogels. 
The buckled chain of the guluronic acid units is a two-dimensional analogue of a 
corrugated egg-box with interstices in which the calcium ions may pack and be 
coordinated (McHugh, 1987). "The analogy is that the strength and selectivity of 
cooperative binding is determined by the comfort with which 'eggs' of the particular 
size may pack in the 'box', and with which the layers of the box pack with each other 
around the eggs". The calcium alginate formed is porous and is known to be 
insoluble and resistant in acidic media (Grant et al., 1973). 
Generally sodium alginate solution is dropped into an aqueous solution of calcium 
chloride through the use of hypodermic needles leading to the precipitation of 
calcium alginate beads (Figure 2). These beads are then filtered and dried by air 
convection and freeze drying, leading to the formulation of porous systems which 
can be buoyant for over 12 hours. Such beads have been demonstrated to extend 
gastric retention time to beyond 5.5 hours (Garg and Gupta, 2008, Whitehead et al., 
1998). 
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3.4.2.2.3. Microporous compartment systems 
In these systems, the drug reservoir is inside a compartment containing pores in the 
surrounding membrane (Harrigan, 1977). The peripheral walls are sealed completely 
in order to avoid any direct contact of the undissolved drug with the gastric contents. 
The entrapped air in the floatation chamber causes buoyancy in the gastric fluid 
(Vyas and Khar, 2006). The gastric fluid passes through the apertures, dissolving the 
drug, thereby providing a reservoir of dissolved drug for continuous drug transport. 
 
3.4.2.2.4. Hollow microspheres  
Microspheres have been widely exploited in this area of gastroretention and floating 
microspheres or hollow microspheres combine the advantages of floating systems 
outlined above along with those of multiple unit systems. 
 
4. Microparticles as drug delivery devices  
Microencapsulation is the mechanism used by approximately 65% of all sustained 
release systems (Gad, 2008). It is a process of application of a thin coating to 
individual core materials with an arbitrary particle size range from 5-5000 mm 
(Lachman et al., 1986). Microencapsulation may cause an improvement in 
absorption of drug and reduction of side effects such as gastrointestinal mucosa 
irritation (Obeidat and Price, 2006). The process is also used to achieve controlled 
release of drugs (Vandegaer, 1974). Single unit dosage forms are known to have the 
disadvantage of an all or nothing emptying process from the stomach, whereas 
multiple unit systems such as microspheres can avoid the unpredictable gastric 
emptying. There is also a reduced risk of dose dumping, with the use of multiple drug 
units rather than single unit dosage forms  The uniform distribution of these multiple 
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unit systems could lead to a more reproducible and predictable drug absorption and 
lower risk of local drug irritation; thus the combination of floatation (Hirtz, 1985) and 
mucoadhesive capability with microencapsulation is a promising strategy for success 
in this application. 
The use of microspheres in sustained drug delivery has attracted much attention in 
recent years, especially with the use of naturally occurring biodegradable polymers, 
controlling the rate of drug release and targeting drugs to specific sites in the body 
(Patel and Patel, 2007, Gohel and Amin, 1998, Woo et al., 2001, Capan et al., 2003). 
Examples of polymers used in the preparation of microspheres of various sizes 
include chitosan and albumin to deliver drugs at a controlled rate to the target sites 
(Singla and Chawla, 2001, Gupta and Hung, 1989). Other examples include gelatin, 
waxes, sodium alginate, and ethyl cellulose (Ahmed et al., 2010). Microspheres have 
been reported to have a high loading capacity (Daharwal et al., 2007) and can be 
formulated with sufficient buoyancy to float in the gastric contents and remain in 
stomach for prolonged periods (Pawar et al., 2011). Such microspheres are 
prepared by a process of solvent evaporation or solvent diffusion/evaporation 
methods (Kawashima et al., 1992). In addition to improving patient compliance by 
decreasing dosing frequency; improved therapeutic effects with drugs with short  
half-life drugs can be achieved (Gaba 2008). Microspheres can also help mask the 
taste of bitter drugs, e.g. roxithromycin (Gao et al., 2006).  
Several methods have been used by researchers in production of microspheres 
(Benita et al., 1984, Bodmeier and McGinity, 1987a, Bodmeier and McGinity, 1987b, 
Jeffery et al., 1993). The methods include solvent evaporation; hot melt 
microencapsulation; solvent removal; spray drying and phase inversion 
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microencapsulation. The most common method is the emulsion solvent –evaporation 
technique (Kawashima et al., 1992) because of its simplicity and the fact that small 
batches of samples can be produced (Quintanar-Guerrero et al., 1998b, Quintanar-
Guerrero et al., 1998a, Swarbrick and Baylan, 1994, Scholes, 1998, Mathiowitz et 
al., 1999).  
 
4.1. Characterisation of microspheres  
Microspheres are characterized by their micromeritic properties such as particle size, 
tapped density, compressibility index, true density, flow properties including angle of 
repose, scanning electron microscopy. For floating microspheres, scanning electron 
microscopy (SEM) can be used to evaluate the internal structure of the microspheres 
and confirm the hollow nature of microspheres. The particle sizes of microspheres 
can be measured using laser diffraction particle size analyzers.  Larger microspheres 
can be measured using an optical microscope and the mean particle size can be 
calculated by determining the mean of 200-300 particles with the use of a calibrated 
ocular micrometer or through the sieving method. The sieving method involves 
separating the microspheres into different size fractions by sieving for a required 
time using a mechanical sieve shaker. 
 
4.1.1. Buoyancy studies  
An in vitro floatability study is usually performed in a USP II dissolution apparatus. 
The test is carried out by spreading the microspheres over simulated gastric fluid (for 
example HCl/NaCl with 0.02% Tween 80, pH1.2) and this fluid simulates the surface 
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tension of human gastric juice (35-50 mN/m2) (El-Gibaly, 2002). The gastric medium 
is maintained at 37°C and stirred at 100rpm.. At specific time intervals, the relative 
proportions of the floating microspheres and the settled microspheres are noted and 
the buoyancy of the microspheres can be calculated using this formula (Kawashima 
et al., 1991). 
   Buoyancy (%) = QF / QF +Qs   X 100     Equation 1  
 
Where Qf and Qs are the masses of the floating and settled microspheres respectively. 
 
Some microspheres have been reported  to float for more than 12 hours in vitro  
following such studies (Kawashima et al., 1991, Kawashima et al., 1992, Soppimath 
et al., 2001a). 
 In vivo floating studies have been assessed by X-ray photographs of the floating 
microspheres loaded with radio-opaque materials, such as  barium sulphate in the 
stomach of animals, e.g. healthy beagle dogs (Tanwar et al., 2007). In this study, the 
animals were fasted for 12 hours and the first X-ray was photographed to ensure 
absence of radio-opaque materials in the stomach. Barium sulphate-loaded cellulose 
acetate microspheres were administered during the course of the study and the 
animals were allowed free access to water. The quantity of barium sulphate added 
was sufficient to ensure visibility by X-ray, but low enough to enable the 
microspheres to float. The radiographs of the abdomen were taken at predetermined 
time intervals and the microspheres floated for 3.2 hours in vivo, compared with 12 
hours in the in vitro studies.  
Gamma scintigraphy has been used successfully to study gastric residence of drug 
dosage forms. In a study by Jain et al., optimized floating microspheres consisting of 
calcium silicate as the porous carrier replaginide and Eudragit® were evaluated. 
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Gamma scintigraphy was used to monitor the transit of floating and non-floating 
microspheres labelled with Technetium-99 (99mTc) in twelve one-year old healthy 
male albino rabbits. The animals were fasted for 12 hours, prior to the start of the 
experiment. Upon administration of the microspheres, the animals were allowed 
access to sufficient volume of drinking water. The location of the formulation in the 
stomach was monitored by keeping the subjects in front of the gamma camera. The 
sequential camera images indicated that the floating microspheres remained 
buoyant for over 6 hours and were uniformly distributed in the gastric contents .The 
non-floating microspheres were buoyant for less than  2 hours (Jain et al., 2006b). In 
vitro studies of similar floating microspheres, showed that more than 80% of the 
microspheres were buoyant for at least 10 hours (Jain et al., 2005). 
Gamma scintigraphy has also been used to assess the buoyancy of microspheres in 
healthy human volunteers (Ma et al., 2008) and GI transit of floating and non-floating 
alginate microspheres. In vitro studies showed that coating of these microspheres 
with chitosan had no effect on buoyancy, as both coated and uncoated microspheres 
floated over simulated gastric fluid (pH 1.2). The human volunteers were not on any 
regular medication and did not have any history of GI disease as with the animal 
models. After an overnight fast, the volunteers were allowed to consume a breakfast 
after taking 100 ml of water containing 20mCi (99mTcO-4). In vivo, prolonged 
gastroretention was observed for over 5 hours for coated floating microspheres 
labeled with Technetium-99 (99mTc), while non-floating units, sank rapidly to the base 
of the stomach and were emptied from the stomach within 2.5 hours.  
 
4.1.2. Evaluation of mucoadhesiveness 
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In vitro evaluation of mucoadhesiveness of amoxicillin microspheres can be studied 
by assessing the percentage of remaining microspheres on the stomach mucosa of 
rats (Liu et al., 2005) after an in vitro wash off test. The rats were fasted overnight 
and dissected immediately after being sacrificed. The stomachs were removed and 
cut into small pieces and rinsed with physiological saline. One hundred microspheres 
were scattered uniformly on the stomach mucosa with the mucosa mounted in a 
chamber maintained at 93% relative humidity and at room temperature. After 20 min, 
the tissues were taken out and fixed on a polyethylene support at an angle of 45°. 
The stomach was rinsed with pH 1.3, HCl - physiological saline solutions for 5 min at 
a rate of 22 ml/min. The microspheres remaining on the surface of gastric mucosa 
were then counted, and the percentage of the remaining microspheres was 
determined to be 93% for the mucoadhesive microspheres and 89% for non- 
mucoadhesive microspheres. In this study, in vivo studies were carried out using rats 
that were kept fasted until they were sacrificed 2, 4 and 7 hours after administration 
of the microspheres. The microspheres remaining in the gastrointestinal tract were 
counted, and the percentage of remaining microspheres was determined to be 65%, 
63% and 4% over the various time intervals for the mucoadhesive microspheres and 
55%, 16%, 4% for the non-mucoadhesive microspheres. 
GI transit study using radio-opaque markers or radiation emitting doses including X-
ray and gamma scintigraphy has also been used to assess mucoadhesion (Säkkinen 
et al., 2006, Chary et al., 1999) 
 
4.2. Polymers used in microparticulate drug delivery 
The type of polymer used in microsphere production determines the properties of the 
microspheres such as the surface characteristics, force of adhesion, buoyancy, 
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release pattern and clearance. Examples of polymers used in development of 
mucoadhesive microspheres include chitosan and  Carbopol® 934P, which has been 
used by many researchers  (Chickering et al., 1995, Chun et al., 2005a) because of 
its good mucoadhesive and biodegradable properties (Patel and Chavda, 2008). 
Other suitable polymers include hydrogels or thermoplastics, homopolymers, 
copolymers or blends, natural or synthetic polymers. 
4.2.1. Carbopol® 
The mucoadhesive capability of Carbopol®  can be easily affected by factors such as 
pH and ionic strength (Singla et al., 2000). At low pH, (i.e. less than 5.0), there is 
limited ionisation of carboxyl groups resulting in reduced polymer swelling and thus 
stronger interaction with polysaccharides in mucus. There have been contradictory 
reports regarding the mucoadhesive properties of Carbopol®. Nagahara et al. 
prepared mucoadhesive microspheres by dissolving amoxicillin, curdlan (matrix) and 
carboxyvinyl polymer (adhesive polymer) in melted hydrogenated castor oil. In vivo 
mucoadhesive tests showed that the microspheres demonstrated longer GRT  in the 
stomach of rat models (Nagahara et al., 1998) . However, in a similar study, it was 
observed that Carbopol® did not increase the gastric residence time of the 
microspheres Carbopol® coated amoxicillin-resin microspheres (Cuna et al., 2001). 
The strength of the adhesive forces between Carbopol® and the mucous layer 
depends on the distribution state of Carbopol® in the microspheres, that is whether 
the polymer is used as a coat layer or is dispersed within the microspheres (Akiyama 
et al., 1995). In vitro and in vivo tests showed those with dispersed Carbopol® 
exhibited stronger mucoadhesion than those with Carbopol® coating. 
4.2.2. Chitosan  
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Chitosan has positive charges in its D-glucosamine residue, which can lead to a 
strong electrostatic interaction with mucus or negatively charged sialic residues of 
mucin (He et al., 1998, Fiebrig et al., 1995). Also, chitosan has -OH and -NH2  groups 
which can lead to hydrogen bonding and the linear molecule possesses some 
degree of chain flexibility , the conformation of which depends on the ionic strength 
(He et al., 1998). These properties are considered important for mucoadhesion to 
occur (Peppas and Buri, 1985, Smart et al., 1984); Robinson et al., 1987(Robinson 
and Mlynek, 1995). Its use as a matrix for sustained release granules (Hou et al., 
1985) and sustained release tablets (Akbuga, 1993, Kawashima et al., 1985) was 
widely studied as early as the 1980s. 
The importance of the mucoadhesive properties of chitosan has been reported in 
works by (Lehr et al., 1992, Fiebrig et al., 1995, Illum et al., 1994, Lueben et al., 
1994, Aspden et al., 1996). Chitosan microspheres with small particle sizes less than 
5 µm, containing anticancer agents such as 5-fluorouracil (5-FU) (Ohya et al., 1993), 
and magnetic microspheres (Hassan et al., 1992), have been described for site- 
specific delivery. Its use in the preparation of microspheres are somewhat limited by 
its comparatively  low strength and non-floating properties in simulated gastric fluid 
(pH 1.2) (Kas, 1997) . 
4.3. Gastroretentive microparticles 
The use of microspheres in oral drug delivery is limited by the short GRT, similar to 
other conventional dosage forms. Therefore, the use of gastroretentive microspheres 
tends to permit the localisation of the drug component in the GI mucosal membrane 
for an extended period of time. This improves the bioavailability, leading to a 
reduction in the dose and frequency of administration. The control of the location of a 
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delivery system at a particular site in the GI tract especially the upper GI tract , often 
improves the absorption of the drug  and the therapeutic effect of the drug (Singh 
and Robinson, 1988). 
 
4.3.1. Mucoadhesive microparticles 
Bioadhesive/mucoadhesive microspheres are a useful and promising delivery 
system, adhering to the mucosal layer, meanwhile releasing their drug contents in a 
sustained manner (Illum, 1998). Such microspheres can either consist entirely of a 
bioadhesive polymer or an outer coating by attaching bioadhesive / mucoadhesive 
materials to the microspheres (Figure 3). Bioadhesive microspheres can be modified 
to adhere to any form of mucosal tissue. They have the added advantage of efficient 
absorption and improved bioavailability of drug content due to the high surface to 
volume ratio, an intimate contact with the mucosal layer and they could help target 
specific absorption sites (Lehr et al., 1992, Henriksen et al., 1996, Bhaskara and 
Sharma, 1997, Chowdary and Rao, 2003).. Studies have shown that there was 
improved bioavailability from mucoadhesive systems containing drugs such as 
testosterone and its esters, vasopressin (Morimoto et al., 1991), dopamine (Ikeda et 
al., 1992) , insulin (Nagai et al., 1984) and gentamycin (Illum et al., 1989). There are 
however, challenges in the development of particles with adequate drug loading for 
their intended application. Loadings of 26%, as reported for amoxicillin 
mucoadhesive microspheres raises concerns both about the efficiency of the 
process and the amount of material that would need to be delivered to achieve 
therapeutic levels (Liu et al., 2005). 
30 
 
Mucoadhesive acyclovir microspheres were prepared by a emulsion-chemical 
crosslinking technique using chitosan, thiolated chitosan, Carbopol 71G and 
Methocel K15M (Dhaliwal et al., 2008). The microspheres showed release of 78.8 
±3.9% in 12 hours compared with a release of 90.5±3.6% in 1 hour from the drug 
powder. The thiolated chitosan microspheres showed better retention at 8.0±0.8h. 
Studies also showed that the administration of these thiolated chitosan microspheres 
could maintain plasma concentration of the drug for about 24 hours as compared to 
5 hours after its administration in solution and showed a nearly four- fold higher 
AUC0-24 value .Chitosan, Carbopol and Methocel showed mucoadhesion times of 
3.1±0.4h, 1.1±0.2h and 0.2±0.1h.  (Dhaliwal et al., 2008) 
Chitosan microspheres containing lacidipine have also been evaluated in vitro for the 
treatment of pyloroplasm. The entrapment efficiency, using glutaraldehyde as the 
cross-linking agent, was between 14-40.82% and the microspheres exhibited a 
mucoadhesive property of over 70% in the in vitro wash off test using rat stomach 
mucosa. The entrapment efficiency and the mucoadhesion depended on the polymer 
concentration, volume of cross-linker and the stirrer speed. The optimal formulation 
showed controlled release for more than six hours and release followed Higuchi 
kinetics (Sultana et al., 2009). 
 
 
4.3.1.1. Application of mucoadhesive microparticles to eradication of H. pylori  
Helicobacter pylori (Figure 4) is a spiral gram-negative micro-aerophilic bacterium, 
with unipolar-sheathed flagella.  The flagella provide motility and the bacterium has 
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the ability to penetrate the gastric mucosa, resist gastric emptying and remain in the 
gastric mucosa, due to its spiral shape and high motility (Conway, 2005). 
The major problem relating to the antibiotic treatment of this infection is that after 
infection, the bacterium resides below the gastric mucus adherent to the gastric 
epithelium; therefore, the access of drugs to this particular site is rather limited. In 
addition, the bacteria could  have acquired  resistance to the commonly used 
antimicrobial drugs (Iijima et al., 2004). The first line therapy for the treatment of this 
infection is the use of a triple therapy consisting of one proton pump inhibitor (PPI) 
and two antibiotics. The antibiotics have to be used in combination, as only one 
antibiotic cannot achieve adequate eradication when used alone and there is a 
requirement for adjuvant therapy (Chang et al., 2003). The adjuvant therapy consists 
of drugs that increase alkalinity in the stomach, in order to allow the local action of 
antibiotics that are not active in acidic pH of the stomach, for example, proton pump 
inhibitors used at a dose equivalent to 20mg omeprazole twice daily. 
A combination of two antibiotics including clarithromycin, amoxicillin and 
metronidazole with a gastric acid inhibitor has been classified as the most effective 
therapy for the eradication of H. pylori (Lahej et al., 1999). However, the persistent 
rise in resistance of this bacterium to these antibiotics; the hostile environment of the 
stomach; reducing antibiotic bioavailability at the site of action has led to failures in 
treatment (Batchelor et al., 2007) and has encouraged research into producing 
alternatives to the commonly used formulations and gastroretentive formulations 
hold particular promise. 
Patel and Chavda (2008) developed amoxicillin microspheres with Carbopol® 934P 
as the mucoadhesive polymer and ethylcellulose as the carrier polymer. The 
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microspheres produced were spherical, free flowing and with entrapment efficiencies 
ranging from 20% to 56%. The microspheres adhered to gastric mucous layer over 
an extended period of time and the release of drug from these microspheres was 
sustained for more than 12 hours. In vivo tests also showed that the microspheres 
exhibited better H. pylori clearance than amoxicillin administered as a dry powder 
(Patel and Chavda, 2008). In a similar study by Yellanki et al., amoxicillin-trihydrate 
microspheres were prepared using Carbopol® 934P and ethylcellulose, the 
entrapment efficiency was between 78-86%. The particle size ranged from 500-560 
µm for all the batches produced. In vitro tests were carried out using sheep gastric 
mucosa rinsed with hydrochloric acid buffer for 5 minutes at a rate of 22 ml/minute. 
More than 84% of the microspheres were retained on the mucosa after 5 minutes 
and drug release was biphasic, with an initial burst release and then followed by a 
slow release with more than 80% drug released after 6 hours (Yellanki et al., 2010).  
Liu et al. prepared ethylcellulose microspheres with Carbopol® 934P as the 
mucoadhesive polymer and amoxicillin as the active drug. The sizes of microspheres 
ranged from 400-1000 µm. The microspheres had a dense but porous inner core and 
release was pH-dependent. In acidic medium (HCl- pH 1.0), 90% of the drug was 
released in 4 hours, while in phosphate buffer (pH 7.8), the release was about 50%. 
In vitro studies showed that 93.5% of the microspheres containing Carbopol® were 
retained in the gastric mucosa of rats, compared with 85.8±5.3% of those without 
Carbopol®.  In vivo studies in rats showed that the mucoadhesive microspheres were 
retained for longer, gastric amoxicillin concentrations were higher and there was 
enhanced clearance of H. pylori (Liu et al., 2005). 
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It was reported in a study that the gastric retention in rats of amoxicillin microspheres 
prepared by dispersing Carbopol® in waxy hydrogenated castor oil, was about three 
times higher than that obtained using amoxicillin suspension containing 0.5% w/v 
methylcellulose, after 2 and 4 hours with about 47% and 20% retained respectively 
for the microspheres and 17% and 6% for the amoxicillin suspension. In addition, the 
mucoadhesive microspheres achieved a 10 times higher bactericidal activity, than 
the amoxicillin suspension in rats (Nagahara et al., 1998). 
In a study by Patel and Patel, the in vitro and in vivo characteristics of mucoadhesive 
microspheres were evaluated. Chitosan was used as the mucoadhesive polymer and 
glutaraldehyde as the cross-linking agent. In vitro tests showed that the amoxicillin 
mucoadhesive microspheres were retained more strongly on the gastric mucous 
layer and could be retained in the GI tract for an extended period of time. The best 
formulation produced in this research, exhibited a high drug entrapment efficiency of 
70% and swelling index of 1.39. The percentage mucoadhesion was 79% after 1 
hour and drug release was sustained for more than 12 hours. The in vivo clearance 
studies showed that mucoadhesive microspheres had a better clearance effect on H. 
pylori than amoxicillin powder. Following administration of a dose of 4 mg/kg 
amoxicillin mucoadhesive microspheres, the colony counts (a measurement of the 
growth of H. pylori) were 23 ± 7.07, and as the doses were increased to 7.5 and 15 
mg/kg the colony counts were reduced to 5.5 ± 0.70 and 2 ± 0, respectively. 
However, following administration of amoxicillin powder (4 mg/kg) the colony counts 
were 78±8.48, and as the doses were increased to 7.5 and 15 mg/kg, the colony 
counts were 29 ± 5.65 and 17.5 ± 17.67, respectively (Patel and Patel, 2007). 
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Wang et al. produced modified gelatin microspheres using aminated gelatine by 
surfactant-free emulsification in olive oil followed by a cross-linking reaction with 
glutaraldehyde. These modified microspheres exhibited a greater gastric 
mucoadhesiveness than the unmodified gelatine microspheres; thereby, presenting 
a likely new candidate DDS for the eradication of H-pylori. There are however safety 
concerns in using glutaraldehyde as a cross-linking agent and residual levels need to 
be controlled (Wang et al., 2000) . 
Ramteke et al., (2006), prepared oral mucoadhesive sustained release nanoparticles 
of clarithromycin, with the aim of simplifying administration, thereby improving 
compliance, therapeutic effect and reducing dose related side effects of the therapy. 
The maximum drug entrapment was 73%, while the percentage nanoparticle 
recovery was reported to be 88%. The drug formulation was proved to reside in the 
stomach of rats for a longer period of time as some nanoparticles still remained in 
the stomach of rats 6 hours after administration. They were retained in the stomach 
for a longer period than clarithromycin suspensions or conventional drug 
formulations (Ramteke et al., 2006). 
Cuna et al., prepared amoxicillin loaded ion-exchange resins encapsulated in 
mucoadhesive polymers such as polycarbophil and Carbopol® 934. An oil-in-oil 
solvent evaporation technique was modified to produce these microparticles 
containing multiple amoxicillin-resin cores. Polycarbophil microparticles were 
spherical, while those containing Carbopol® were irregularly shaped. In vitro release 
of amoxicillin was rapid despite the polymer coating. GI transit in rats was 
investigated by fluorescence microscopy using particles loaded with fluorescein 
instead of amoxicillin; GRT was longer, and the particles were more evenly 
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distributed over the stomach when uncoated. It was also observed that Carbopol® 
did not help increase the GRTof the microspheres. Such discrepancies may be due 
to the method of administration, the amount of polymer used and the swelling ability 
of the formulation as outlined previously. 
4.3.1.2. Improving targeting of mucoadhesive microspheres 
Targeted drug delivery is a selective and effective localization of pharmacologically 
active compound at specific targets in therapeutic concentrations, while restricting its 
access to other sites, thus minimising the toxic effects and maximising the 
therapeutic index (Gregoriadis and Florence, 1993).  Mucoadhesive polymers exhibit 
the ability to stick to wet mucosal surfaces by non-specific physicochemical 
mechanisms, such as hydrogen bonding. With this non-specific binding, the polymer 
is unable to differentiate between adherent or shed-off mucus, limiting their ability to 
target a specific tissue. The development of microspheres coupled with cell specific 
ligands has increased therapeutic benefit and enhanced the possibility of effective 
site-specific drug delivery (Chowdary and Rao, 2004). Any ligand that has a high 
binding affinity for mucin can be linked covalently to microspheres. Examples of such 
ligands include lectins, adhesins, antibodies and certain amino acid sequences. 
4.2.1.2.1. Lectins:. There has been interest in lectins due to their ability to bind 
specifically to membrane bound sugar moieties located at the cell surface of 
epithelial cells, enhancing the  adherence of microparticles to the intestinal 
epithelium and improving the absorption of drugs (Lee et al., 2000).).Lectins are 
found in plants, vertebrates (Ashwell and Harford, 1982, Stockert and Morell, 1983), 
bacteria and invertebrates (Lis and Sharon, 1986) but the plant lectins are the largest 
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group of known lectins. Based on their molecular structure, lectins can be divided 
into three categories: 
 Monolectins - those having only one carbohydrate recognising domain 
 Hololectins - those with two or more carbohydrate recognising domains  
 Chimerolectins – those with additional unrelated domains  
 
They have the potential to target drugs to different parts of the GI tract or even to 
different cells (e.g. complex-specific lectins for parietal cells or fuco-specific lectins 
for M cells). Coating of polystyrene microparticles with tomato lectins has been 
demonstrated to facilitate specific binding with enterocytes (Gabor et al., 1997). 
Following cellular uptake, they subsequently exhibit strong binding to nuclear pore 
membranes (Haas and Lehr, 2002).  Another important advantage of lectins in 
mucoadhesive drug delivery to the GI tract is their resistance to digestion within that 
environment.  
Montisci et al. investigated the behaviour of two plant lectin-particle conjugates after 
oral administration. The two lectins, Lycopersicon esculentum L. and Lotus 
tetragonolobus are specific for oligomers of N-acetyl-D-glucosamine and L-fucose, 
respectively and they were conjugated to small poly(lactide) microspheres. The 
overall GI transit of the particles was strongly delayed, when the microspheres were 
conjugated to the lectins, mainly due to the gastric retention of the particles. A 
significant fraction of the conjugates adhered to the gastric and intestinal mucosa. 
No significant differences were observed after a preliminary incubation of lectin-
microsphere conjugates with specific sugars showing that the activity could be 
maintained (Montisci et al., 2001). 
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Jain and Jangdey prepared and characterized lectin-conjugated clarithromycin 
microspheres for the effective colonization of H. pylori. Ethylcellulose (EC) 
microspheres were prepared using the emulsification/evaporation method. Drug 
entrapment efficiency was about 70% and conjugation with Concanavalin-A (Con-A) 
was confirmed by IR spectroscopy and differential scanning calorimetry.  Con-A is a 
lectin isolated from the jack bean, Canavalia ensiformis and  binds specifically to 
mono, oligo- and polysaccharides with terminal non-reducing α-D-mannopyranosyl-, 
α-D-glucopyranosyl- or β-D-fructofuranosyl residues. Maximum mucoadhesion of 
85% was observed in Con-A conjugated EC microspheres on stomach mucosa of 
rats, compared with 12% observed in non-conjugated microspheres. A GRT of over 
6 hours was reported in rabbits for Con-A conjugated microspheres of clarithromycin, 
while it was 3 hours for an optimised clarithromycin tablet formulation (Jain and 
Jangdey, 2009). 
In another study by Umamaheshwari and Jain, lectin-conjugated nanoparticles were 
prepared as a means of attaching acetohydroxamic acid delivery system on the 
carbohydrate receptors of H-pylori. Ulex europaeus Agglutinin I (UEA I) and Con-A 
lectins were bound to gliadin nanoparticles (GNP) by a two-stage carbodiimide 
coupling technique.  The binding efficacy of the lectin to the carbohydrate receptors 
was evaluated and this showed strong agglutination patterns with mannose-specific 
Con A-GNP and (L)-fucose specific UEA-GNP formulations. The lectin formulations 
completely inhibited H. pylori binding with human stomach cells. The antimicrobial 
activity of the formulations was evaluated by percent growth inhibition studies by 
using isolated H. pylori strain. The inhibitory efficacy of UEA-GNP and Con A-GNP 
was approximately two-fold higher compared to unconjugated nanoparticles 
(Umamaheshwari and Jain, 2003). 
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4.2.1.2.2.  Bacterial adhesins: Bacterial fimbriae are long lectin-like proteins found 
on the surface of many bacterial strains, through which they attach to the epithelial 
surfaces of enterocytes. Their presence has been associated with pathogenicity. 
Therefore, DDS  based on this technique could be an efficient mechanism to 
enhance adhesion of bioadhesive microspheres to epithelial surfaces (Lee et al., 
2000).  
Bernkop-Schnurch et al. covalently attached a fimbrial protein –K99 to poly (acrylic 
acid) polymer in order to improve the adhesion of the DDS to the GI epithelium. K99 
was isolated from an E-coli strain harbouring the fimbriae-encoding plasmid 
pR19906. In this study, the function of the fimbrial protein was tested using a 
haemagglutination assay, along with equine erythrocytes expressing the same K99-
receptor structures as those of GI-epithelial cells. A 10-fold slower migration of the 
equine erythrocytes through the K99-poly (acrylic acid) gel, compared to the control 
gel without the fimbriae was demonstrated, indicating the strong affinity of the K99-
fimbriae to their receptor on the erythrocytes (Bernkop-Schnürch et al., 1995). 
 
4.2.1.2.3. Amino acid sequences 
Some amino acid sequences have complementary parts on the cell and on the 
mucosal surfaces and when they are attached to microparticles, this can enhance 
binding to specific cell surface glycoproteins (Vasir et al., 2003). In the disease state 
the cell surface glycoproteins are altered and theses altered protein sequences can 
be a target by complementary amino acid sequences attached to drug delivery 
devices. Dihydroxyphenylalanine (DOPA) an amino acid is found in mussel adhesive 
protein (MAP) and is believed to lend to the adhesive process. DOPA has been 
combined with Pluronics to enhance their adhesion (Huang et al., 2002). With its 
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favourable safety profile, MAP seems to be a suitable compound for the 
development of mucoadhesive DDS, preferably if these can be manufactured and 
stored under non-oxidative conditions (Schnurrer and Lehr, 1996). 
Antibodies can be produced against some selected molecules present on mucosal 
surfaces. Antibodies could be a rational choice for designing site-specific 
mucoadhesives, due to the high level of specificity of the antibodies and this is 
especially useful in targeting drugs to tumour tissues. 
4.3.2. Floating microparticles 
Several studies have investigated the effect of formulation and process variables 
such as polymer type, drug and polymer ratio , type of solvent, organic solvent ratios, 
concentration of plasticiser in aqueous phase, time of stirring on the yield, particle 
size, loading, release and floating behaviour of microspheres (Lee et al., 1999, 
Streubel et al., 2002, Sato  et al., 2004, Soppimath et al., 2006). Some studies have 
shown that the microspheres remained buoyant in the gastric cavity over a long 
period of time in vivo (Jain et al., 2006b) and the encapsulated drug showed a high 
bioavailability (Joseph et al., 2002, Sato et al., 2003). The encapsulated drug in the 
polymer matrix exhibited varied release patterns such as zero order release (Gibley, 
2002), Higuchi matrix model and Peppas Korsmeyer model (Jain et al., 2006a). 
 Kawashima et al. prepared microspheres containing tranilast – an oral anti-allergic 
agent (Kawashima et al., 1991). The drug and an acrylic polymer were dissolved in a 
combination of solvents containing ethanol and dichloromethane. Increasing the 
polymer ratio led to an increase in the volume of the internal cavity and changing the 
polymer ratio also led to control of the drug release rate. In vitro studies showed the 
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formulation was buoyant for 12 hours, while in vivo radiographical studies showed 
that the formulations were dispersed in the upper part of the human stomach for over 
3 hours. 
The effect of co-excipients on the rate of drug release and buoyancy of microspheres 
were reported in another study (Soppimath et al., 2006). Nifedipine was incorporated 
into cellulose acetate hollow microspheres prepared by solvent diffusion/evaporation 
technique in the presence of co-excipients like polyethylene glycol (PEG), dibutyl 
phthalate (DBP), and poly (ε-caprolactone) (PCL) using ethyl acetate as a dispersing 
solvent. Increasing the concentration of polymer led to an increase in size of the 
microspheres. The microspheres were buoyant in simulated gastric fluid for over 12 
hours, with the blank microspheres being the most buoyant compared with other 
microspheres produced in the series. The presence of co-excipients affected 
buoyancy of the microspheres, with cellulose acetate-polyethylene glycol (CA-PEG) 
microspheres buoyancy was lower and this increased with increasing concentration 
of PEG. However, by increasing the concentration of PEG from 10 to 40%, the 
buoyancy decreased from 51.3 to 11.8%. A better buoyancy of 62–82% was 
observed for microspheres with water-insoluble plasticiser like DBP after 15 h. This 
might be due to the fact that DBP is a hydrophobic plasticiser and it prevents wetting 
as well as water uptake. However, the percentage buoyancy of CA–PCL 
formulations decreases from 26% to 6% with increasing concentration of PCL. The 
nifedipine content of the microspheres was released in a controlled manner and was 
easily modified by changing the process parameters of the formulation. 
Jain et al., prepared repaglinide floating microspheres through the emulsion- solvent 
diffusion technique with calcium silicate as a porous carrier, Eudragit® S as the 
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polymer and ethanol with dichloromethane as solvents  and polyvinyl alcohol as the 
surfactant. The microspheres exhibited a high entrapment efficiency of 75 ± 3.0% 
due to the poor aqueous solubility of the drug. They were predominantly spherical in 
nature with an average particle size of 142-825 µm across various batches. True 
densities ranged from 1.62-1.92 g/cm3 with angle of repose less than 40°. The 
compressibility index ranged from 25.0% to 34.6%. In vitro buoyancy tests were 
carried out by spreading the microspheres over the surface of simulated gastric fluid 
containing Tween 20. The microspheres also exhibited satisfactory buoyancy profile 
with more than 80% of the microspheres still floating for at least 10 hours. It was 
observed however, that microspheres of larger sizes exhibited a longer floating time 
(Jain et al., 2005). 
Srivastava et al., prepared and evaluated cimetidine-loaded floating gastroretentive 
microspheres. The polymers used were hydroxylpropylmethylcellulose and 
ethylcellulose. Effects of the stirring rate during preparation, polymer concentration, 
solvent composition and dissolution medium on the size of microspheres and drug 
release were also observed. The drug was released over approximately 8 hours and 
the microspheres exhibited buoyancy for over 10 hours. Buoyancy percentage of the 
microspheres was in the range of 69% to 87%.  At high polymer concentration, the 
mean particle increased and the drug release rate decreased (Srivastava et al., 
2005). 
In a study by Garg and Gupta, silymarin microspheres were prepared using cellulose 
polymers (hydroxypropyl methyl cellulose and ethyl cellulose) and Eudragit® 
polymers (Eudragit® S 100 and Eudragit® RL), through the emulsion-solvent 
evaporation method. In vitro floatability studies were carried out using the USP XXIV 
42 
 
dissolution apparatus with 0.1M HCl containing 0.02%v/v Tween 80 as the medium 
and the paddles rotating at 100rpm over a period of 12 hours. A large proportion of 
the microspheres remained buoyant with 61% and 75% of the Eudragit® and 
cellulose microspheres respectively floating after 12 hours (Garg and Gupta, 2010).  
Floating chitosan beads containing verapamil were prepared by Yassin et al. The 
physical properties, floating characteristics and release profile of the beads were 
studied. The beads were spherical with a size range of 1.3 to 2.0 mm and the drug 
loading efficiency was around 42% in all the batches. Beads produced using medium 
molecular weight chitosan, exhibited the slowest drug release rate and the shortest 
floating lag time of around 5 minutes and long duration of buoyancy of more than 6 
hours (Yassin et al., 2006). 
Singh et al, developed floating and non-floating beads containing an anti-ulcer drug 
pantoprazole through the simultaneous ionotropic gelation of alginate and sterculia 
gum using calcium chloride as the crosslinker. Calcium carbonate (CaCO3) was used 
as the floating aid. The beads produced showed a drug loading of over 65% and 
were further characterized using SEM and FTIR. Swelling studies showed that the 
swelling of the beads was dependent on the amount of polymer used, crosslinking 
agent and the pH of the media. Release of drug from the beads was by Fickian 
diffusion mechanism and the release of drug from floating beads was less than that 
observed from non-floating beads (Singh et al., 2010). 
In a study by Atyabi et al., microparticles loaded with theophylline and bicarbonate 
were prepared (Atyabi et al., 1996a). The ion-exchange resin beads (Amberlite IRA-
400® and Dowex 2X10®) were coated with a semi-permeable membrane (Eudragit 
RS). Carbon dioxide was released on contact of the beads with the acidic gastric 
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juice (Atyabi et al., 1996b). In vitro studies showed that the microparticles exhibited 
floating times of over 24 hours. The coating of the beads trapped carbon dioxide 
generated in the beads and thereby prolonged the floating time.  In vivo studies with 
human volunteers using gamma-scintigraphy showed a prolonged residence time for 
coated beads (40% to 65% of the dose remained in the beads in the upper stomach 
3 hours after a light breakfast) compared to the uncoated beads for which no beads 
remained in the stomach after 3 hours. 
 
4.3.2.1 Application of floating microparticles for eradication of H. pylori 
Floating acetohydroxamic acid microspheres were developed using polycarbonate 
as the polymer and were prepared by the emulsion solvent evaporation technique. In 
vitro analysis showed that the microspheres exhibited buoyancy with over 70% of the 
microspheres floating over simulated gastric fluid (pH 1.2) containing Tween 20 after 
12 hours (Umamaheshwari et al., 2003). In this study, floating of up to 10 hours was 
considered to be satisfactory.  An increase in the concentration of polymers led to a 
reduction in buoyancy of the microspheres, due to an increase in density. Also, the 
microspheres required a less amount of drug dose in achieving its anti- H. pylori 
activity in rat models, when compared with the drug alone. The microspheres cleared 
the microorganism more effectively than the drug, due to the prolonged GRT of the 
microspheres resulting from the buoyancy of the microspheres. 
There is little research reported on the use of floating microspheres in the eradication 
of H. pylori in the treatment of peptic ulcer and this is an area of research that looks 
promising. However, floating beads have been extensively researched for 
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eradication of H. pylori and results may be used to inform subsequent studies using 
microparticles. 
Metronidazole (MZ) was incorporated into chitosan-treated alginate beads by the 
ionotropic gelation method (Ishak et al., 2007). A (3 × 2 × 2) factorially designed 
experiment  in which three viscosity-imparting polymers- methylcellulose, Carbopol® 
934P and κ-carrageenan; two concentrations (0.2 and 0.4% w/v) of chitosan as 
encapsulating polymer and two concentrations (2.5 and 5% w/w) of the low density 
magnesium stearate as a floating aid were tested. The bead formula containing 0.5% 
κ-carrageenan, 0.4% chitosan and 5% magnesium stearate showed immediate 
buoyancy, optimum drug entrapment efficiency and extended drug release. The 
histopathological examination of mice stomachs and in vivo H. pylori clearance tests 
were carried out by orally administering MZ floating alginate beads or MZ 
suspension, to H. pylori infected mice under fed conditions as a single daily dose for 
three successive days in different doses- 5, 10, 15 and 20 mg/kg.  Groups receiving 
MZ in the form of floating alginate beads at doses 10, 15 and 20 mg/kg showed 
better H. pylori eradication than the corresponding suspension form. The in vivo H. 
pylori clearance tests showed that MZ floating beads with a dose of 15 mg/kg 
provided 100% clearance rate, whereas the MZ suspension with a dose of 20 mg/kg 
gave only 33.33%. 
Rajinikanth and Mishra prepared matrix, gellan gum-based, clarithromycin floating 
beads. Formulation variables such as concentrations of gellan, calcium carbonate 
and drug loading, influenced the in vitro drug release. Differential scanning 
calorimetry confirmed the absence of interactions between drug and polymer. There 
was good anti-microbial activity against isolated H. pylori strain with complete growth 
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inhibition after 12 hours. 80% of the beads remained floating after 1 hour; after 4 and 
6 hours about 60% and 50% of the beads remained floating in rabbit stomach. The 
stability studies of beads did not show any significant changes after storage of 
beads, at 40º C/75% relative humidity for 6 months. The preliminary results from this 
study suggest that floating beads of gellan can be used to incorporate antibiotics like 
clarithromycin and may be effective when administered locally in the stomach 
against H. pylori. (Rajinikanth and Mishra, 2009). 
Metronidazole-loaded alginate beads consisting of calcium silicate as a porous 
carrier or NaHCO3 as a gas-forming agent were prepared for local eradication of H. 
pylori. The silicate based beads showed slower release pattern, compared to the 
gas-forming beads due to network structure strengthening effect of the calcium 
silicate. In addition, the gas-forming-based beads had a shorter buoyancy lag time 
because the NaHCO3 produced larger pores than those of silicate treated ones. Drug 
entrapment efficiency was over 60% for the formulations (Javadzadeh et al., 2010) 
Murata et al. prepared two types of floating alginate beads. The first alginate gel 
bead contained vegetable oil (ALGO) and its buoyancy was due to the oil in the 
alginate gel matrix. The second, (ALCS), was a dried gel bead with dispersed 
chitosan in the matrix. When ALCS containing metronidazole was administered 
orally to guinea pigs, it floated on the gastric juice and released the drug into the 
stomach. In addition, the concentration of drug at the gastric mucosa after 
administration of ALCS was higher than that obtained from metronidazole solution, 
though the metronidazole serum concentration was the same, regardless of which 
type of gel was administered. These release properties of alginate gels are 
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applicable not only for sustained release of drugs, but also for targeting the gastric 
mucosa (Murata et al., 2000). 
 
4.3.3. Floating bioadhesive microparticles 
Dual functioning systems are currently being explored in gastroretentive drug 
delivery. This is achieved through a combination of both the floating and bioadhesive 
systems, which can be exploited to achieve synergy and also help to overcome the 
drawbacks associated with each system. This theory was explored by Chitnis et al 
(1991) and it was proposed that these systems target H. pylori–induced infected 
sites more effectively and could serve to optimize antibiotic monotherapy of H. 
pylori–based infections (Umamaheswari et al., 2002). In the research by 
Umamaheswari et al, floating microspheres containing acetohydroxamic acid were 
prepared. Also, these microspheres were further coated with polycarbophil. The 
microspheres floated for longer than 12 hours, due to the low densities of the 
formulation 0.61-0.85 g/cm3. The coating of the microspheres reduced the release 
rate of the drug and exhibited a better in vitro and in vivo percentage H. pylori growth 
inhibition. 
Zheng et al. also explored this strategy with chitosan alginate-ethylcellulose 
microparticles. The formulation was prepared through a combination of 
emulsification/evaporation and internal/ion gelation methods. In vitro tests showed 
that 74% of the microspheres remained buoyant on an acetate buffer solution for 8 
hours and 90% of the loaded drug was released in a sustained manner over this 
period. In vivo mucoadhesive studies showed that 61% of the microparticles were 
retained in the stomach of male Sprague-Dawley rats for 4 hours.  Pre-treatment 
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with omeprazole led to an increase in clarithromycin concentration with the 
microparticles in the gastric mucosa compared to clarithromycin solution (Zheng et 
al., 2006). 
A floating bioadhesive system was developed for the eradication of H. pylori with 
ethylcellulose as matrix polymer and Carbopol® 934P as the mucoadhesive polymer. 
The microspheres exhibited both strong mucoadhesive and good buoyancy profiles. 
They also demonstrated significant anti H. pylori effect in vivo in Mongolian gerbil 
models. In addition, on comparison with conventional clarithromycin suspension, the 
new formulation required a lower dose of drug for eradication of the microorganism. 
The microspheres also improved the gastric stability of clarithromycin and 
eradication of H. pylori from the GI tract more than conventional formulations due to 
the prolonged gastric retention time of the formulation (Rajinikanth et al., 2008). 
In a randomised clinical trial floating bioadhesive microspheres were compared with 
conventional clarithromycin suspension. In 876 patients, it was observed that at low 
doses of 60 and 90mg/kg of clarithromycin, H. pylori was mostly cleared with a 98-
100% clearance rate and 83% inhibition at clarithromycin dose of 30mg/kg. This 
formulation exhibited a better eradication profile than the suspension and the 
microbial clearance was further confirmed by polymerase chain reaction analysis 
(Vaiciunas et al., 2010). 
Gattani et al. developed alginate/hydroxypropyl methylcellulose-based 
floating/mucoadhesive beads containing clarithromycin to extend the contact time of 
the antibiotic with H pylori. The beads were prepared by the ionic- gelation technique 
with calcium chloride as the gelating agent and liquid paraffin (LP) was incorporated 
to aid the floating of the beads. Drug loading efficiency was more than 80%, in all 
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batches of the formulation with particle size within the range of 0.7 mm-1.1 mm. SEM 
images of the beads presented a rough surface with characteristic large wrinkles and 
micropores. Floating ability of beads depended upon the percentage of LP used in 
the preparation of beads.  The formulations without LP were not buoyant and those 
containing more than 10% LP showed 100% buoyancy. As the concentration of LP 
increased, the release rate decreased. In vitro mucoadhesion studies showed that 
alginate beads exhibited up to 80% mucoadhesion and there was no significant 
effect of the LP on the mucoadhesive property of the beads, while Alg-HPMC beads 
showed 100% mucoadhesion. Ex-vivo mucoadhesion study shows floating-
mucoadhesive beads of Alg-HPMC have better adhesive effect in the stomach and 
might stay longer in the stomach for more effective H. pylori clearance. In vivo X-ray 
imaging study showed  that the Alg-HPMC beads of CL remained buoyant for at 
least 6 h in rabbit stomach and that they had good floatability in vivo (Gattani et al., 
2010). 
Sahasathian et al prepared amoxicillin- loaded alginate beads, coated with 0.5% w/v 
chitosan and the beads exhibited drug encapsulation efficiency and 
mucoadhesiveness which was over 90%, 100% buoyancy was achieved and the 
beads achieved sustained release of amoxicillin for over 6 hours in simulated gastric 
fluid (Sahasathian et al., 2010). 
  
5. Conclusion 
There is no doubt that the oral route is the most common and probably most 
complex route of drug delivery. The major barriers against achieving successful 
delivery of drugs via the oral route include unpredictable gastric emptying times, 
shorter gastrointestinal transit time of the dosage form, partial drug release from the 
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dosage form and the absorption site of the particular drug. The application of 
controlled release gastroretentive microparticles has the potential to resolve most of 
these problems. However, in the eradication of H. pylori, the ideal dosage form 
should in addition to overcoming all these barriers, also be able to target the 
bacterium. Most studies show excellent in vitro sustained release and eradication 
profiles, which do not often correlate to in vivo results. Therefore, more research is 
required into gastroretentive microparticulate formulations that will exhibit excellent in 
vitro and in vivo eradication results against H. pylori and a reliable in vitro method to 
assess their potential.  
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Theory  Mechanism of Bioadhesion  Comments  
Electronic 
theory 
There are attractive 
electrostatic forces between 
the glycoprotein mucin 
network and the 
bioadhesive material 
 
Electron transfer occurs between the 
mucin and the bioadhesive material  
forming a double layer of electric charge 
at the interface 
Adsorption 
theory 
There are surface forces 
resulting in chemical 
bonding 
The surface forces include strong primary 
forces which are  covalent bonds and  
weak secondary forces which include 
ionic bonds, hydrogen bonds and van der 
Waal’s forces 
Wetting 
theory 
The ability of bioadhesive 
polymers to spread and 
develop intimate contact 
with the mucus membranes 
 
Spreading coefficients of polymers must 
be positive. Contact angle between 
polymer and cells must be near to zero 
 
Diffusion 
theory 
Physical entanglement of 
mucin strands and the 
flexible polymer chains 
For maximum diffusion and best 
bioadhesive strength: solubility 
parameters (δ) of the bioadhesive 
polymer and the mucus glycoproteins 
must be similar interpenetration of mucin 
strands into the porous structure of the 
polymer substrate 
Fracture 
theory 
Analyses the maximum 
tensile stress developed 
during detachment of the 
bioadhesive drug delivery 
system from the mucosal 
surfaces 
 
Does not require physical entanglement 
of bioadhesive polymer chains and mucin 
strands, hence appropriate to study the 
bioadhesion of hard polymers, which lack 
flexible chains 
 
  
Table 1: Mechanism of bioadhesion-Adapted from Vasir et al., (2003). Used with permissions. 
 
 
 
